Literature DB >> 29132462

[Familial male-limited precocious puberty due to Asp578His mutations in the LHCGR gene: clinical characteristics and gene analysis in an infant].

Min Wang1, Min Li, Yue-Sheng Liu, Si-Min Lei, Yan-Feng Xiao.   

Abstract

The aim of the study was to provide a descriptive analysis of familial male-limited precocious puberty (FMPP), which is a rare inherited disease caused by heterozygous constitutively activating mutations of the luteinizing hormone/choriogonadotropin receptor gene (LHCGR). The patient was a ten-month-old boy, presenting with penile enlargement, pubic hair formation, and spontaneous erections. Based on the clinical manifestations and laboratory data, including sexual characteristics, serum testosterone levels, GnRH stimulation test, and bone age, this boy was diagnosed with peripheral precocious puberty. Subsequently the precocious puberty-related genes were analyzed by direct DNA sequencing of amplified PCR products from the patient and his parents. Genetic analysis revealed a novel heterozygous missense mutation c.1732G>C (Asp578His) of the LHCGR gene exon11 in the patient, which had never been reported. His parents had no mutations. After combined treatment with aromatase inhibitor letrozole and anti-androgen spironolactone for six months, the patient's symptoms were controlled. The findings in this study expand the mutation spectrum of the LHCGR gene, and provide molecular evidence for the etiologic diagnosis as well as for the genetic counseling and prenatal diagnosis in the family.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29132462

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  2 in total

1.  [Reconsideration of the third-generation non-steroidal aromatase inhibitors in pediatrics].

Authors:  Chunlin Wang; Li Liang
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-05-25

2.  Long-Term Treatment With Letrozole in a Boy With Familial Male-Limited Precocious Puberty.

Authors:  Xin Yuan; Ruimin Chen; Ying Zhang; Xiaohong Yang; Xiangquan Lin
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-14       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.